Redefining cosmetic hair density

The cosmetic hair thinning category has long lacked credible, science-led innovation.

Follicopeptide® is a patent-protected peptide gel serum built on Swedish research and developed to support visibly fuller-looking hair.

Redefining cosmetic hair density

The cosmetic hair thinning category has long lacked credible, science-led innovation.

Follicopeptide® is a patent-protected peptide gel serum built on Swedish research and developed to support visibly fuller-looking hair.

What is Follicopeptide?

Follicopeptide® is a patent-protected cosmetic peptide developed for visible hair thinning.

It is formulated as a water-free, leave-on gel serum designed for precise scalp application and long-term cosmetic use.

The formulation has demonstrated visible improvement in the appearance of hair density in thinning areas and is suitable for both men and women.

Key benefits

Patented peptide
technology

Improves the appearance
of hair density

Hormone-independent

Suitable for both
men and women

Once daily
application

Scientific foundation

Follicopeptide originates from academic research at Lund University and has been translated into a patented cosmetic formulation designed for topical use.

The formulation integrates a fully synthetic cosmetic peptide and has been clinically evaluated for cosmetic use, demonstrating visible improvement in the appearance of hair density in thinning areas.

Market opportunity

Visible hair thinning affects a significant share of both men and women globally, with up to 50% of adults experiencing thinning over their lifetime.

Despite strong consumer demand, the cosmetic category continues to face challenges related to credibility, realistic expectations and long-term adherence. This creates demand for science-led cosmetic solutions designed to deliver visible, appearance-based improvement without medicinal positioning.

Adjacent categories such as eyelash and eyebrow serums represent additional growth opportunities. The global eyelash serum market is estimated at approximately USD 770 million and the eyebrow segment at USD 289 million.

Several leading products in these segments are based on prostaglandin analogues, a category that has attracted regulatory attention in cosmetic use, reinforcing demand for alternative, compliant cosmetic approaches.

Commercial platform

Follicopeptide is a patent-protected, science-led cosmetic platform addressing visible hair thinning across multiple distribution formats.

The gel serum is currently commercialized through selected European partners, with additional portfolio extensions under development in adjacent categories such as eyebrows and eyelashes.

The commercial model is designed for flexibility, supporting private label, clinic-based and branded retail partnerships within a compliant cosmetic framework.

For partnership or investment opportunities, please contact Coegin Pharma CEO Jens Eriksson: je@coeginpharma.com